- Trials with a EudraCT protocol (288)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
288 result(s) found for: SARS coronavirus.
Displaying page 4 of 15.
EudraCT Number: 2020-001759-42 | Sponsor Protocol Number: 214094 | Start Date*: 2020-05-20 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease. | |||||||||||||
Medical condition: Severe pulmonary COVID-19 related disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) ES (Completed) BE (Completed) DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005197-25 | Sponsor Protocol Number: C4591031 | Start Date*: 2022-02-22 | |||||||||||
Sponsor Name:BioNTech SE | |||||||||||||
Full Title: A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSE(S) OF BNT162b2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162b2 | |||||||||||||
Medical condition: Protection against COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001517-21 | Sponsor Protocol Number: I4V-MC-KHAA | Start Date*: 2020-06-30 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients with COVID-19 Infection | |||||||||||||
Medical condition: COVID-19 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001264-28 | Sponsor Protocol Number: P2-IMU-838-COV | Start Date*: 2020-05-28 | |||||||||||
Sponsor Name:Immunic AG | |||||||||||||
Full Title: A Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator’s Choice of Standard of Ca... | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BG (Completed) RO (Completed) GR (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001010-38 | Sponsor Protocol Number: Ahus-NO-COVID-19 | Start Date*: 2020-03-23 | |||||||||||
Sponsor Name:Akershus University Hospital | |||||||||||||
Full Title: NORWEGIAN CORONAVIRUS DISEASE 2019 (NO COVID-19) STUDY: AN OPEN LABELED RANDOMIZED CONTROLLED PRAGMATIC TRIAL TO EVALUATE THE ANTIVIRAL EFFECT OF CHLOROQUINE IN ADULT PATIENTS WITH SARS-COV-2 INFEC... | |||||||||||||
Medical condition: SARS-COV-2 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001587-29 | Sponsor Protocol Number: 02/04/2020-001 | Start Date*: 2020-04-08 | |||||||||||
Sponsor Name:Barcelona Institute for Global Health (ISGlobal) | |||||||||||||
Full Title: Hydroxychloroquine efficacy in preventing SARS-CoV-2 infection and CoVid-19 disease severity during pregnancy | |||||||||||||
Medical condition: SARS-SoV-2 infection and CoVid-19 disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002537-15 | Sponsor Protocol Number: R10933-10987-COV-2066 | Start Date*: 2020-10-06 | ||||||||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS CoV 2 Monoclonal Antibodies for the Treatment of Hospitalized Patients with COVID-19 | ||||||||||||||||||
Medical condition: Coronavirus disease 2019 (COVID-19) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: RO (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-001951-42 | Sponsor Protocol Number: ReCOVery-SIRIO | Start Date*: 2020-05-08 | |||||||||||
Sponsor Name:Uniwersytet Mikołaja Kopernika w Toruniu | |||||||||||||
Full Title: Amiodarone or Verapamil in COVID-19 hospitalized patients with symptoms: Randomized clinical trial | |||||||||||||
Medical condition: Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001385-11 | Sponsor Protocol Number: PrEP_COVID_19 | Start Date*: 2020-03-28 | |||||||||||
Sponsor Name:Plan Nacional Sobre SIDA | |||||||||||||
Full Title: Prevention of SARS-CoV-2 (COVID-19) through Pre-Exposure Prophylaxis with Tenofovir disoproxil/Emtricitabine and Hydroxychloroquine in Healthcare Personnel: Randomized Clinical Trial controlled wit... | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001440-26 | Sponsor Protocol Number: PrevenCOVID-19 | Start Date*: 2020-04-19 |
Sponsor Name:Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI) | ||
Full Title: Pilot, double-blind clinical trial to evaluate the efficacy and safety of pre-exposure use of hydroxychloroquine versus placebo in the prevention of SARS-CoV-2 (COVID-19) infection in healthcare pe... | ||
Medical condition: Prevention of SARS-CoV-2 (COVID-19) infection | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001591-15 | Sponsor Protocol Number: NL73430.091.20 | Start Date*: 2020-04-09 | |||||||||||
Sponsor Name:Radboudumc | |||||||||||||
Full Title: Reducing hospital admission of elderly in SARS-CoV-2 pandemic via the induction of trained immunity by bacillus Calmette-Guérin vaccination, a randomized controlled trial. | |||||||||||||
Medical condition: SARS-CoV-2 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001038-36 | Sponsor Protocol Number: BNT162-01 | Start Date*: 2020-04-20 | |||||||||||
Sponsor Name:BioNTech SE | |||||||||||||
Full Title: A multi-site, Phase I/II, 2-part, dose escalation trial investigating the safety and immunogenicity of four prophylactic SARS-CoV-2 RNA vaccines against COVID-19 using different dosing regimens in ... | |||||||||||||
Medical condition: Protection against COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001736-95 | Sponsor Protocol Number: ACCORD-2-001,Sub002,003,006 | Start Date*: 2020-04-28 | |||||||||||
Sponsor Name:University Hospital Southampton NHS Foundation Trust | |||||||||||||
Full Title: ACCORD 2: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID 19 in Hospitalised Patients | |||||||||||||
Medical condition: COVID 19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002091-12 | Sponsor Protocol Number: HUVE-19-CT-001 | Start Date*: 2020-05-15 |
Sponsor Name:HUVEPHARMA EOOD | ||
Full Title: Multicenter, randomized, double-blind, placebo-controlled study investigating efficacy, safety and tolerability of ivermectin HUVE-19 in patients with proven SARS-CoV-2 infection (COVID-19) and man... | ||
Medical condition: confirmed SARS-CoV-2 infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BG (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001565-37 | Sponsor Protocol Number: PrEP_COVID | Start Date*: 2020-04-03 |
Sponsor Name:ISGlobal | ||
Full Title: PRE-EXPOSURE PROPHYLAXIS WITH HYDROXYCHLOROQUINE FOR HIGH-RISK HEALTHCARE WORKERS DURING THE COVID-19 PANDEMIC (PrEP_COVID): A UNICENTRIC, DOUBLE-BLINDED RANDOMIZED CONTROLLED TRIAL. | ||
Medical condition: COVID-19 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001435-27 | Sponsor Protocol Number: CHUBX2020/12 | Start Date*: 2020-04-10 |
Sponsor Name:CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX, ETABLISSEMENT PUBLIC | ||
Full Title: Home treatment of elderly patients with symptomatic SARS-CoV-2 infection (COVID-19) : a multiarm, multi-stage (MAMS) randomized trial to assess the efficacy and safety of several experimental treat... | ||
Medical condition: severe acute respiratory syndrome coronavirus 2(SARS-CoV 2) | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005410-18 | Sponsor Protocol Number: 2020/ABM/COVID19/0036 | Start Date*: 2020-12-02 |
Sponsor Name:Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie Samodzielny Publiczny Zakład Opieki Zdrowotnej | ||
Full Title: Multicentre, randomized, double-blind, placebo-controlled, non-commercial clinical trial to evaluate the efficacy and safety of specific anti-SARS-CoV-2 immunoglobulin in the treatment of COVID-19 | ||
Medical condition: CoronaVirus Disease 2019 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: PL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2020-003278-37 | Sponsor Protocol Number: INSIGHT-014-ACTIV-3 | Start Date*: 2020-09-04 | ||||||||||||||||
Sponsor Name:Regents of the University of Minesota | ||||||||||||||||||
Full Title: A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients with COVID-19 | ||||||||||||||||||
Medical condition: Subjects infected with SARS-CoV-2, admitted to the hospital due to COVID-19. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) GB (GB - no longer in EU/EEA) SE (Prematurely Ended) PL (Completed) GR (Completed) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-001270-29 | Sponsor Protocol Number: EFC16858 | Start Date*: 2020-04-08 | |||||||||||
Sponsor Name:sanofi-aventis recherche & développement | |||||||||||||
Full Title: An adaptive Phase 2/3, randomized, open-label study assessing efficacy and safety of hydroxychloroquine for hospitalized patients with moderate to severe COVID-19 | |||||||||||||
Medical condition: Coronavirus infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended) FR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000316-31 | Sponsor Protocol Number: HIDR-0721/COV | Start Date*: 2021-07-15 |
Sponsor Name:FAES FARMA S.A. | ||
Full Title: Multicenter, double-blind, randomized clinical trial to evaluate the efficacy of calcifediol soft capsules versus placebo in reducing hospital admissions in patients with a positive diagnostic test... | ||
Medical condition: SARS-CoV-2 coronavirus infection (COVID-19). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
